Study of the pharmacokinetic variability of azacytidine

Loïc Osanno(Institut national de recherche en sciences et technologies du numérique), Raphaëlle Fanciullino(Inserm), Laure Farnault(Aix-Marseille Université), Geoffroy Venton(Inserm), Julien Colle(Inserm)

HAL AMU

July 3, 2023

Cited by 0

Related Papers

Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines

|Journal of the American Heart Association|2020|298

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition

|Blood|2021|157

Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors

|Blood Cancer Journal|2016|74

High incidence of atrial fibrillation in patients treated with ibrutinib

|Open Heart|2019|72

Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications

|Clinical and Developmental Immunology|2012|60